MARGIN CONTROL FOR LENTIGO-MALIGNA

被引:132
作者
ROBINSON, JK
机构
[1] Chicago, Illinois
关键词
D O I
10.1016/S0190-9622(94)70140-7
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Lentigo maligna is an in situ malignant melanoma for which the treatment of choice is surgical excision. The current recommendation is local resection with a 0.5 to 1.0 cm margin of normal skin. Because many lesions occur on the face, the narrowest possible margin reduces the amount of scarring. Controversy surrounds the use of Mohs micrographic surgery to preserve normal skin and resect the lentigo maligna. Objective: The purposes of this prospective study were to determine the narrowest possible margin of resection of lentigo maligna and the accuracy of frozen and fixed histologic specimens from those margins. In addition, the benefit of adjunctive immunoperoxidase staining with antibodies to S-100 protein and HMB-45 monoclonal antibody was examined retrospectively. Methods: A Wood's light was used to delineate the clinical margin in 16 cases of lentigo maligna that were resected with serial excisions 0.3, 0.6, 1.0, and 1.3 cm from the clinical border of the tumor. Frozen sections were confirmed by fixed histopathologic specimens. Subsequently these tissue blocks were examined with antibodies to S-100 protein and HMB-45 monoclonal antibodies. Patients were observed 5 to 9 years. Results: One of the 16 patients had a recurrence 8 years after surgery. Although lesions with a diameter less than 2.0 cm had narrower margins of resection, the majority of lesions were resected with a margin of 0.6 to 1.0 cm. Lesions larger than 3.0 cm in diameter required a margin of resection greater than 1.0 cm. The antibody to S-100 protein was neither sensitive nor specific enough to assist with identification of the process. HMB-45 monoclonal antibody was sensitive and assisted in the identification of atypical melanocytes.
引用
收藏
页码:79 / 85
页数:7
相关论文
共 51 条
[21]  
HERSEY P, 1991, 2ND INT S EP MAL MEL
[22]  
HOLMAN CDJ, 1986, J NATL CANCER I, V76, P403
[23]  
HOLMAN CJD, 1989, J NATL CANCER I, V73, P75
[24]   THE VALUE OF IMMUNOHISTOCHEMICAL STUDIES USING ANTIBODY TO S100 PROTEIN IN DERMATOPATHOLOGY [J].
KAHN, HJ ;
BAUMAL, R ;
MARKS, A .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1984, 23 (01) :38-44
[25]   FOLLOWING LENTIGO MALIGNA MAY NOT PREVENT THE DEVELOPMENT OF LIFE-THREATENING MELANOMA [J].
KELLY, JW .
ARCHIVES OF DERMATOLOGY, 1992, 128 (05) :657-660
[26]   THE RECOGNITION OF RECENTLY DESCRIBED AND POTENTIALLY PROBLEMATIC MELANOCYTIC LESIONS OF THE SKIN [J].
LUPTON, GP ;
GAGNIER, JM .
DERMATOLOGIC CLINICS, 1992, 10 (01) :161-187
[27]  
MCGILLIS ST, 1991, J DERMATOL SURG ONC, V17, P681
[28]   MELANOMA IN PEOPLE AGED 65 AND OVER IN SCOTLAND, 1979-89 [J].
MCHENRY, PM ;
HOLE, DJ ;
MACKIE, RM .
BRITISH MEDICAL JOURNAL, 1992, 304 (6829) :746-749
[29]   APPARENT PROGRESSION OF LENTIGO MALIGNA TO INVASIVE MELANOMA DURING TREATMENT WITH TOPICAL AZELAIC ACID [J].
MCLEAN, DI ;
PETER, KK .
BRITISH JOURNAL OF DERMATOLOGY, 1986, 114 (06) :685-689
[30]   CHEMOSURGERY FOR MELANOMA [J].
MOHS, FE .
ARCHIVES OF DERMATOLOGY, 1977, 113 (03) :285-291